04:51 PM EDT, 10/20/2025 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) said Monday it entered into a licensing and supply agreement with Prestige Biopharma to market Tuznue, a biosimilar to Herceptin, also known as trastuzumab, in most European markets.

Tuznue, approved by the European Commission in September 2024, is indicated for HER2-positive breast and metastatic gastric cancers, Teva said.

Prestige will produce and supply the drug, while Teva will manage marketing and distribution across Europe.